| 5/7/2021 |
Global Kidney Cancer Diagnostics and Therapeutics Market Growth, Size, Share, Industry Report and Forecast 2021-2027 |
Wordpress.com |
... the growth of the global kidney cancer market. Development in treatment therapy such as immunotherapy is projected to generate huge prospects for the market.To Request a Sample of our Report on Global Kidney Cancer Diagnostics and Therapeutics Market : https://www.omrglobal.com/request-sample/kidney-cancer-diagnostics-and-therapeutics-marketImmunotherapy has less injuriousness than chemotherapy which creates it more suitable for senior people. Immunotherapy demonstrates a fast and constant reaction ... |
| 5/6/2021 |
Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program | Financial Buzz |
financialbuzz.com |
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, has been selected as the winner of the “Best New Technology Solution for Oncology” award in the fifth annual MedTech Breakthrough Awards program. The award recognizes Castle’s DecisionDx®-SCC and DecisionDx® DiffDx™-Melanoma genomic tests, both newly launched in the second half of 2020.Castle Biosciences ... |
| 5/4/2021 |
Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S. | Business Wire |
Business Wire |
Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S. May 04, 2021 07:00FRIENDSWOOD, Texas- Castle Biosciences , Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, is a national sponsor of the Colorado Melanoma Foundation, a non-profit organization. Castle will collaborate with the Colorado Melanoma Foundation and Epiphany Dermatology ... |
| 5/4/2021 |
Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S. |
Business Insider |
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, is a national sponsor of the Colorado Melanoma Foundation, a non-profit organization. Castle will collaborate with the Colorado Melanoma Foundation and Epiphany Dermatology to provide free skin cancer screenings and public education through the Sun Bus initiative. The Sun Bus is a mobile skin cancer screening station and sun safety ... |
| 4/27/2021 |
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory | Business Wire |
Business Wire |
FRIENDSWOOD, Texas- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it has signed a definitive agreement to acquire all of the equity of Myriad myPath, LLC (Myriad myPath Laboratory), from Myriad Genetics. Myriad myPath Laboratory is a CLIA-certified laboratory in Salt Lake City, where the myPath Melanoma 23-gene expression profile (GEP) test was developed and ... |
| 4/27/2021 |
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory |
Business Insider |
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it has signed a definitive agreement to acquire all of the equity of Myriad myPath, LLC (Myriad myPath Laboratory), from Myriad Genetics. Myriad myPath Laboratory is a CLIA-certified laboratory in Salt Lake City, where the myPath Melanoma 23-gene expression profile (GEP) test was developed and is currently ... |
| 4/27/2021 |
|
malvern-online.com |
Castle Biosciences, Inc. ( Nasdaq: CSTL ), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it has signed a definitive agreement to acquire all of the equity of Myriad myPath, LLC (Myriad myPath Laboratory), from Myriad Genetics. Myriad myPath Laboratory is a CLIA-certified laboratory in Salt Lake City, where the myPath Melanoma 23-gene expression profile (GEP) test was developed and is currently ... |
| 4/27/2021 |
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory - Stocks News Feed |
stocksnewsfeed.com |
... difficult-to-diagnose melanocytic lesions.The Company to host a conference call today at 7:30 a. m . E.T.FRIENDSWOOD, Texas–(BUSINESS WIRE)– $CSTL DiffDxMelanoma – Castle Biosciences , Inc. (Nasdaq: CSTL ), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it has signed a definitive agreement to acquire all of the equity of Myriad myPath, LLC (Myriad myPath Laboratory), from Myriad Genetics ... |
| 4/26/2021 |
Colorectal Cancer Diagnostics Market Analysis, Top Players, Target Audience and Forecast to 2027 |
PRSync |
The insight partner - Monday, April 26, 2021.An exclusive Colorectal Cancer Diagnostics Market research report has been fabricated through the in depth analysis of the market dynamics across five regions including North America, Europe, South America, Asia-Pacific, Middle East and Africa.The segmentation of the market by components, end users, and region was done based on the thorough market analysis and validation through extensive primary inputs from industry experts ... |
| 4/26/2021 |
Colorectal Cancer Market Insights: Growth Factors, Market Drivers, Segmentations, Key Players, Analysis & Forecast by 2027 |
packagingnews24.com |
... instance, in December 2016, Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, introduced Colvera, a blood-based diagnostic test for colorectal cancer recurrence monitoring.Thus, the constant developments in colorectal cancer diagnostics and therapeutics are expected to accelerate the market growth during the forecast period.Growing Pharmaceutical Industry In Emerging EconomiesThe rising pharmaceutical industry in the developing countries in the Asia Pacific region are creating ... |
| 4/23/2021 |
The Ridgway Record |
ridgwayrecord.com |
Dublin, The "Next Generation Cancer Diagnostics Market Research Report by Technology, by Cancer Type, by Function, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.The Global Next Generation Cancer Diagnostics Market is expected to grow from USD 5,693.79 Million in 2020 to USD 15,738.27 Million by the end of 2025.Cumulative Impact of COVID-19:COVID-19 is an incomparable ... |
| 4/23/2021 |
Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population |
Business Insider |
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, will present data at the American Academy of Dermatology’s Virtual Meeting Experience, being held April 23 – 25, 2021. The Company has two poster presentations highlighting its DecisionDx®-Melanoma and DecisionDx®-SCC genomic tests. Data presentation information is as follows: DecisionDx ® -Melanoma: The poster is entitled, "Risk ... |
| 4/23/2021 |
Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population | Financial Buzz |
financialbuzz.com |
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, will present data at the American Academy of Dermatology’s Virtual Meeting Experience, being held April 23 – 25, 2021. The Company has two poster presentations highlighting its DecisionDx®-Melanoma and DecisionDx®-SCC genomic tests.Data presentation information is as follows:DecisionDx ® -Melanoma:The poster is entitled, “Risk ... |
| 4/22/2021 |
Tumor Genomics Industry Trends, Revenue, Size, Analysis, Key Players, Growth, Share and Forecast Till 2028 |
sbwire.com |
... in the field is another key factor driving market growth. Increasing research on cancer, usage of genomic systems among academics and government institutions, and decreasing cost of sequencing is contributing significantly to growth in cancer diagnostics . The report captures the essence of the market, offering details on its different valuations, present scenario, volume consumption, revenue share over the projected period. In addition, the report largely focuses on delivering information regarding ... |
| 4/22/2021 |
Castle Biosciences Presents Data at the Dermatology Nurses Association 2021 Annual Convention | Financial Buzz |
financialbuzz.com |
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced participation in the Dermatology Nurses’ Association 2021 Annual Convention. Castle presented posters highlighting each of the company’s three skin cancer gene expression profile (GEP) tests.Poster information is as follows:DecisionDx ® -Melanoma:The poster is entitled, “31-gene expression profiling improves risk stratification in patients with ... |
| 4/22/2021 |
The Ridgway Record |
ridgwayrecord.com |
... the intellectual property rights to the proprietary breast cancer blood test, Videssa®, and has a diagnostic testing laboratory currently performing COVID-19 PCR testing, primarily for the medical and entertainment industries.The breast cancer diagnostics market reached a size of over $19 Billion in 2019, according to a September 2020 market report published by Global Market Insights. In many cases, current tools often cannot provide diagnostic certainty in identifying ... |
| 4/22/2021 |
Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa Breast Cancer Blood Test |
newmediawire.com |
... the intellectual property rights to the proprietary breast cancer blood test, Videssa®, and has a diagnostic testing laboratory currently performing COVID-19 PCR testing, primarily for the medical and entertainment industries. The breast cancer diagnostics market reached a size of over $19 Billion in 2019, according to a September 2020 market report published by Global Market Insights. In many cases, current tools often cannot provide diagnostic certainty in identifying ... |
| 4/22/2021 |
· Todos plans to commercialize Videssa in late 20 |
wapakdailynews.com |
... the intellectual property rights to the proprietary breast cancer blood test, Videssa®, and has a diagnostic testing laboratory currently performing COVID-19 PCR testing, primarily for the medical and entertainment industries.The breast cancer diagnostics market reached a size of over $19 Billion in 2019, according to a September 2020 market report published by Global Market Insights. In many cases, current tools often cannot provide diagnostic certainty in identifying ... |
| 4/22/2021 |
Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa Breast Cancer Blood Test |
otcmarkets.com |
... the intellectual property rights to the proprietary breast cancer blood test, Videssa®, and has a diagnostic testing laboratory currently performing COVID-19 PCR testing, primarily for the medical and entertainment industries.The breast cancer diagnostics market reached a size of over $19 Billion in 2019, according to a September 2020 market report published by Global Market Insights. In many cases, current tools often cannot provide diagnostic certainty in identifying ... |
| 4/22/2021 |
Paige and Leica Biosystems Partner to Expand Access to Computational Pathology Products for Pathology and Oncology Research | Business Wire |
Business Wire |
NEW YORK & VISTA, Calif.--( BUSINESS WIRE )-- Paige , a global leader in AI-based digital diagnostics, and Leica Biosystems , a globally recognized cancer diagnostics and workflow solution leader, today announced a strategic partnership to expand access to computational pathology products for clinical and translational research. The partnership brings Paige’s AI-enabled research software for tumor detection, grading and quantification to Leica Biosystems digital pathology platform in select countries throughout North ... |